Picard Medical Unveils Next-Gen Artificial Heart at ISHLT 2026
Event summary
- Picard Medical's SynCardia will present its next-generation total artificial heart platform at ISHLT 2026 on April 24, 2026.
- The presentation, titled 'The Emperor Total Artificial Heart: A Fully Implantable Solution for End Stage Heart Failure,' will highlight ongoing development.
- SynCardia will also exhibit at booth 409, showcasing its existing SynCardia Total Artificial Heart (STAH).
- STAH is the only commercially available total artificial heart approved by both the U.S. FDA and Health Canada.
The big picture
Picard Medical's presentation at ISHLT 2026 underscores its leadership in artificial heart technology, a field critical for patients with end-stage heart failure. With over 2,100 implants across 27 countries, the company is expanding access to life-sustaining therapies. The next-generation platform could further solidify its position in a market increasingly focused on fully implantable solutions.
What we're watching
- Regulatory Approval
- Whether the next-generation platform will secure regulatory approvals as swiftly as the current STAH.
- Market Adoption
- The pace at which the new platform could gain market traction, given the existing STAH's global footprint.
- Competitive Dynamics
- How this innovation positions Picard Medical against emerging competitors in mechanical circulatory support.